You have 9 free searches left this month | for more free features.

City

Chang Chun (1)

Jilin (1)

Qingdao (1)

ShangHai (1)

Condition

ALK Rearrangement Non-small Cell Lung Cancer (1)

ALK-positive NSCLC (1)

Healthy (1)

Non-small Cell Lung Cancer (1)

ROS1 Rearrangement Non-small Cell Lung Cancer (1)

Overall Status

Not yet recruiting (3)

Recruiting (1)

Sign in for free

Phase

phase 1 (2)

phase 2 (1)

phase 3 (1)

Sponsor

Xuanzhu Biopharmaceutical Co., Ltd. (4)

Collaborator

Intervention

xzp-3621 (4)

crizotinib (1)

Study Documents

Intervention Type

drug (4)

Funder Type

Industry (4)

Study Type

Interventional (4)

xzp-3621

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

ALK-positive NSCLC Trial in Jilin (XZP-3621)

Not yet recruiting

ALK-positive NSCLC

XZP-3621

Jilin, Chang Chun, China

Jilin Province Cancer Hospital

Jul 29, 2022

Healthy Trial in Qingdao (XZP-3621)

Not yet recruiting

Healthy

XZP-3621

Qingdao, Shandong, China

The Affiliated Hospital of Qingdao University

Aug 27, 2021

NSCLC Trial in Chang Chun (XZP-3621, Crizotinib)

Not yet recruiting

Non-small Cell Lung Cancer

XZP-3621
Crizotinib

Chang Chun, Ji Lin, China

Jilin Province Cancer Hospital

Jan 10, 2022

ROS1 Rearrangement NSCLC, ALK Rearrangement NSCLC Trial in ShangHai (XZP-3621)

Recruiting

ROS1 Rearrangement Non-small Cell Lung Cancer
ALK Rearrangement Non-small Cell Lung Cancer

XZP-3621

ShangHai, Shanghai, China

Shanghai Chest hospital affiliated to Shanghai jiao tong univers

Sep 14, 2021